ERBB2 expression as potential risk-stratification for early cystectomy in patients with pT1 bladder cancer and concomitant carcinoma in situ

• Verfasst von: Breyer, Johannes [VerfasserIn]
• Verfasst von: Erben, Philipp [VerfasserIn]
• Verfasst von: Kriegmair, Maximilian [VerfasserIn]
• Titel: ERBB2 expression as potential risk-stratification for early cystectomy in patients with pT1 bladder cancer and concomitant carcinoma in situ
• Verf.angabe: Johannes Breyer, Wolfgang Otto, Ralph M. Wirtz, Bernd Wullich, Bastian Keck, Philipp Erben, Maximilian C. Kriegmair, Robert Stoehr, Markus Eckstein, Mark Laible, Kornelia Schlombs, Sebastian Eidt, Stefan Denzinger, Maximilian Burger, Arndt Hartmann, on behalf of the BRIDGE Consortium
• E-Jahr: 2017
• Jahr: April 2017
• Umfang: 8 S.
• Fussnoten: Gesehen am 04.04.2018
• Titel Quelle: Enthalten in: Urologia internationalis
• Ort Quelle: Basel : Karger, 1955
• Jahr Quelle: 2017
• Band/Heft Quelle: 98(2017), 3, Seite 282-289
• ISSN Quelle: 1423-0399
• DOI: doi:10.1159/000453670
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1571694269

Abstract

Background/Aims/Objectives: It is difficult to identify patients with a non-muscle-invasive bladder cancer (NMIBC) at stage pT1 with concomitant carcinoma in situ (Cis) who will benefit from an early cystectomy. Methods: We retrospectively analyzed clinical data and formalin-fixed paraffin-embedded tissues of patients with NMIBC. Messenger ribonucleic acid (mRNA) expression of progesterone receptor (PGR), estrogen receptor (ESR1), ERBB2, and marker of proliferation Ki-67 (MKI67) was measured by single-step reverse transcription quantitative real-time polymerase chain reaction using RNA-specific TaqMan assays. Relative gene expression was determined by the normalization of 2 reference genes (CALM2, B2M) using the 40 ΔΔCT method and relative gene expression was correlated to the histopathological stage and oncological outcome. Results: Of 302 patients with pT1 NMIBC in the initial transurethral resection of the bladder, 65 had a concomitant Cis. Elevated ERBB2 expression (>40.1) significantly correlated with progress in patients with and without concomitant Cis (p = 0.020 and p = 0.049, respectively). For the subgroup of pT1 with concomitant Cis, elevated ERBB2 expression significantly discriminated between a high-risk group of 55% progression-free survival (PFS) and a low-risk group of 90% PFS after a 5-year follow-up (p = 0.020). Cox-regression analysis revealed ERBB2 expression as the only independent prognostic factor for PFS (p = 0.0037). Conclusions: High mRNA expression of ERBB2 can identify patients with pT1 NMIBC with concomitant Cis, who have a high risk of progression and might benefit from an early cystectomy.